Cure8 research brief
Patients with IBD often have joint and skin comorbidities that drive symptoms and treatment choices.
This study suggests JAK inhibitors can improve many common extraintestinal problems in treatment-experienced IBD patients and that improvement in peripheral spondyloarthritis may associate with better steroid-free IBD remission rates.
Adult IBD patients (UC or Crohn's) with joint or skin EIMs/IMIDs, clinicians managing complex IBD with extraintestinal disease, and researchers studying real-world effectiveness of JAK inhibitors.
The study pooled 246 treatment-experienced IBD patients starting a JAK inhibitor and measured EIM/IMID and IBD activity at set timepoints. Observed response rates were generally favorable post-induction and at 12 months for several EIMs (e.g., peripheral SpA 82% post-induction, 74% at 12 months; axial SpA 71% and 59%; psoriasis 65% and 50%).
About 31% discontinued treatment; filgotinib use and having both axial and peripheral SpA were linked to higher discontinuation risk. The article is an observational, retrospective real-world study: it reports physician global assessments and observed response rates, and uses regression to identify associations.
It does not replace randomized trial evidence, and treatment decisions should be individualized with a clinician.
This is a retrospective multicenter study using physician global assessment rather than blinded outcome measures; most patients had prior advanced therapies, which may affect generalizability. The study reports associations, not causal proof, and discontinuation reasons and safety details should be reviewed in the full paper.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: ECCO National Study Group
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...
This analysis summarizes longer-term safety data for upadacitinib (Rinvoq) in people with moderate to severe ulcerative colitis and Crohn’s disease.
People with IBD or Crohn's disease considering or taking upadacitinib may worry about rare but serious risks such as heart attacks, strokes, or blood clots. This meta-analysis found no clear increase in those events...
